Meeting
2016 Genitourinary Cancers Symposium
Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).
Authors
Guillermo de Velasco
Dana-Farber Cancer Institute, Boston, MA
Guillermo de Velasco , Diana Miao , Sachet Shukla , Martin Henner Voss , Catherine Wu , Bradley Murray , Matthew Meyerson , Sabina Signoretti , Robert J. Motzer , Eliezer Mendel Van Allen , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 545)
DOI
10.1200/jco.2016.34.2_suppl.545
Abstract #
545
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
First Author: Jose Antonio Lopez Guerrero
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
First Author: Hirotaka Miyashita
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang